Business Wire

BOW Group Closes Series B Funding

Jaa

The BOW Group announces today that it has closed its series B funding, led by PM Equity Partner (PMEP) and NextStage, the investment company listed on the Euronext Paris regulated exchange, NextStage, also participated in the financing round. BOW (Be Over the World) Group is a fast growing and consumer driven Internet-Of-Things (IOT) specialist, operating worldwide in the wearables, connected vehicles and smart home markets with 3 distinctive brands MyKronoz, RoadEyes and Deconnect.

“This new round of funding will enable us to expand our international presence to 100 countries by 2018 and to consolidate our leadership position in Europe while accelerating the development of innovative products and services within the IOT space. These investments will allow us to take the steps needed to fulfill our ambition to become a billion-dollar company in the next 5 years,” says Boris Brault, Chairman and CEO of BOW Group. Mr. Brault remains BOW’s majority shareholder.

Since its 2015 €10 million series A financing led by NextStage, BOW Group has demonstrated strong growth and profitable operations. BOW has over the last few years gained significant expertise in developing and launching IOT products through digital marketing and community engagement. Fueled by ambition and innovative vision, BOW Group has proven its ability to conquer new markets through a bold and winning commercial strategy combining traditional retail and digital channels. BOW has today sold more than 2.5 million devices.

The Swiss wearable brand MyKronoz is a strong asset of BOW Group. MyKronoz has in less than 4 years, established itself as a fierce challenger to both tech and traditional watchmakers, and is now considered one of the most promising startups in the smartwatch industry.

“Having backed BOW Group from its early beginning and helped them structure the 3 companies, we are proudly witnessing their ability to deliver innovations and scale up their business to compete in this fast-moving landscape. The Internet of Things market is set to hit $267B by 2020, and we are confident to be in an even stronger position today to take part, together, in this revolution,” says Nicolas de Saint Etienne, BOW Board member and Managing Partner at NextStageAM.

About BOW: BOW (Be Over the World) Group is a fast-growing and consumer-driven IOT specialist, operating worldwide in the wearables, connected vehicles and smart home markets with 3 distinctive brands MyKronoz, RoadEyes and Deconnect.
Among its recent successes, there is the launch of ZeTime, MyKronoz’s newest unique hybrid smartwatch introduced onto online crowdfunding platforms. With over $6,000,000 raised and goods already shipped out to more than 30,000 backers, ZeTime became the biggest 2017 project on Kickstarter and Indiegogo, and the largest one ever from a European company.
In addition, MyKronoz, with its Swiss DNA and unique position of delivering stylish wearable devices at an affordable price, ranks as the best-selling IOT brand within the retail network of the leading French telecom operator Orange, boosting its ambition to duplicate this commercial success to many more mobile carriers around the world. More recently, MyKronoz has been selected by Amazon to join their Launchpad program, and is pleased to be considered as one of the strategic wearable brands by the world’s leading ecommerce platform.

About NextStage:
NextStage is an investment platform created in March 2015 and listed on the Euronext Paris market (Compartment C) since December 2016. As of June 30, 2017, its Adjusted Net Asset Value represents €160.4 million. NextStage specialises in Medium-Sized Companies (MSCs), which allows access to an unlisted and often inaccessible class of assets that drives growth and performance. It invests in equity with little or no leverage over an unlimited time frame to provide funding for the growth of MSCs, alongside visionary entrepreneurs. NextStage is backed by the know-how and stability of the asset management firm NextStage AM, which was founded in 2002. NextStage has already closed twelve investment transactions (as of September 30, 2017) since its inception.www.nextstage.com/sca.

About PM Equity Partner:
PM Equity Partner is the corporate venture fund of Philip Morris International. For more information see www.pmequitypartner.com.
For information about PMI, see www.pmi.com and www.pmiscience.com

Contact information

Media inquiries
BOW:
Sarah Brault
Chief Marketing Officer
s.brault@bow.lu

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

European Commission approves Ipsen’s Cabometyx® (cabozantinib) for the treatment of hepatocellular carcinoma in adults previously treated with sorafenib15.11.2018 09:30Tiedote

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced that the European Commission (EC) has approved Cabometyx® (cabozantinib) 20, 40, 60 mg as a monotherapy for hepatocellular carcinoma (HCC) in adults who have previously been treated with sorafenib. This approval allows for the marketing of Cabometyx® (cabozantinib) in this indication in all 28 member states of the European Union, Norway and Iceland. “Today’s EC approval for the use of Cabometyx ® provides a much needed new option for HCC patients. Until now, physicians in Europe had only one approved therapy for the 2 nd line treatment of this aggressive and difficult-to-treat cancer.1,2 We are proud to offer Cabometyx ® as an innovative treatment that has been shown to extend survival in previously treated patients with HCC,” said Harout Semerjian, Chief Commercial Officer, Ipsen. “This new indication reinforces Ipsen’s commitment to improve patients’ lives through the expansion of the clinical benefit of Cabometyx ® i

Mobidiag nostaa viimeisen €4M erän Euroopan investointipankin €15M rahoituksesta15.11.2018 09:30Tiedote

Mobidiag Oy, vahvassa kasvuvaiheessa oleva molekyylidiagnostiikkayhtiö, joka taistelee antibioottiresistenssin leviämistä vastaan, ilmoitti tänään, että se on nostanut viimeisen 4 miljoonan euron erän 15 miljoonan euron lainasta, jonka Euroopan investointipankki (EIP) myönsi yhtiölle kolmivuotiseen projektiin heinäkuussa 2016. Laina myönnettiin osana EIP:n ”InnovFin - EU Finance for innovators” -ohjelmaa. Ohjelman tavoitteena on tukea innovatiivisten eurooppalaisten yhtiöiden haastavia korkean teknologian kehityshankkeita mahdollistamalla rahoituksen. Tämä lehdistötiedote sisältää multimediaa. Katso koko julkaisu täällä: https://www.businesswire.com/news/home/20181114005789/fi/ Aiemmin nostettujen EIP:n lainaerien avulla Mobidiag on kehittänyt valmiiksi ja kaupallistanut Novodiag® -molekyylidiagnostiikan järjestelmänsä sekä kaksi suolistoinfektioiden aiheuttajien tunnistamiseen käytettävää testiä (Novodiag® C. difficile ja Novodiag® Bacterial GE+). Viimeisen lainaerän avulla yhtiö nope

Mobidiag Receives Final €4M Tranche of €15M EIB Financing15.11.2018 09:30Tiedote

Mobidiag Ltd., a commercial stage molecular diagnostics company addressing the spread of antimicrobial resistance, announced today that it has received the final €4M tranche of a €15M three-year project secured by the Company from the European Investment Bank Group (EIB) in July 2016. The loan was provided as part of “InnovFin – EU Finance for innovators” programme, an EIB initiative aimed at providing innovative and high quality companies in Europe with access to finance. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181114005786/en/ The EIB funding has already enabled Mobidiag to finalize, launch and commercialize its Novodiag® molecular diagnostic system and two assays for detection of gastrointestinal infections (Novodiag® C. difficile and Novodiag® Bacterial GE+). The final tranche will enable the Company to continue growing its product portfolio, accelerate the development of further assays for the Novodiag® system an

Highlights of China’s No. 1 High-Tech Fair CHTF 201815.11.2018 05:00Tiedote

The 20th China Hi-Tech Fair (CHTF 2018) is being held from November 14-18 at the Shenzhen Convention and Exhibition Center with the theme “New Development Concept for High Quality Growth.” This year’s CHTF consists of exhibitions, forums, professional meetings, supporting activities, talents exchange meetings and overseas fairs, and features advanced manufacturing, next-generation information technology, AI, life sciences, new materials, new energy, as well as integration of real economy and future industries. Here are some of the highlights of CHTF 2018: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181114005654/en/ International and Belt & Road Pavilion of CHTF (Photo: Business Wire) Themed areas focusing on industry hotspots The IT exhibition will present themed areas like AI, smart manufacturing, smart automotive, sports technology, big data, cloud computing, IoT and blockchain; the environmental exhibition will highlig

MapleStory Prepares for Epic Battle Against the Black Mage in Gathering of Heroes Event15.11.2018 00:00Tiedote

MapleStory, the iconic global MMORPG from Nexon America, is bringing the first phase of its long-awaited battle with the sinister villain, the Black Mage. Between November 14 through November 28, players can take part in the “Gathering of Heroes” event to join the Maple Alliance and prepare their armies to soon combat the Black Mage. The Black Mage has long been the main antagonist behind MapleStory. His story originated with the role of bringing balance to Maple World, but turned dark as he realized the only way to save Maple World was to destroy it. Now that his seal has been broken, players will need to work together to defeat the legendary boss. The Gathering of Heroes event adds the Maple Alliance outpost, where players can hone their skills and prepare to level up in preparation of for their battle against the Black Mage, as well as adds various leveling updates. The main goal of the Alliance is to gather “Determination” and power up the holy light in the outpost to be able to fi

SpinalCyte Announces Sustained 12-Month MRI Outcomes After CybroCell™ Injection14.11.2018 23:07Tiedote

SpinalCyte, LLC, a Texas-based regenerative medicine company focused on regrowth of the spinal disc nucleus using its universal donor product, CybroCell™, today announced that a single injection of modified human dermal fibroblasts (HDFs), resulted in significant improvements of disc height and pain reduction 12 months after injection of the cell therapy for patients with degenerative disc disease (DDD). The trial assessed patients using the Oswestry Disability Index (ODI), Visual Analogue Scale (VAS) and disc height via MRI scans. Using composite scoring, 54% of the treatment arm patients met all three endpoints as compared to only 17% with the placebo (p=0.0003). Over 84% of patients in the treatment group of CybroCell™ or CybroCell™ with platelet rich plasma (PRP) injections had an increase or no change in disc height compared to 25% for the placebo saline injection. Analyzed individually, 83% of spinal discs that were injected with CybroCell™ had an increase or no change in disc he

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme